This trial of olaparib shows that it may be effective in treating metastatic castration-resistant prostate cancer, with 11 out of 49 patients responding positively to the drug. However, more research is needed to determine the optimal timing for olaparib therapy and whether it is effective in earlier disease states.
1 Primary · 4 Secondary · Reporting Duration: 2 years
50 Total Participants · 1 Treatment Group
Primary Treatment: Olaparib · No Placebo Group · Phase 2
Age 18+ · Male Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: